Sensodyne-Maker Haleon Revenue Rises on Oral Health Growth — Update

By Aimee Look

Haleon booked a rise in organic revenue, led by growth in its oral health segment with brands like Sensodyne toothpaste.

The maker of Panadol and Advil tablets said revenue for the first quarter rose 2.2% on an organic basis, while company-compiled analyst estimates expected organic growth of 2.3%.

Reported revenue rose 0.1% to 2.86 billion pounds ($3.87 billion).

The U.K. consumer health giant's strongest product category was oral health, with 8.3% organic growth--driven by Sensodyne and Parodontax products, Haleon said. The two products had double-digit growth, off the back of geographic expansion and innovation, it said.

The company has leaned into oral health to offset weaker product categories like respiratory and digestive health amid a milder cold and flu season. Growth in oral health was "tempered by a weak cold and flu season," Chief Executive Officer Brian McNamara said.

Organic revenue for its digestive health category, which houses brands like Tums, fell 0.4% on-year for the first quarter. Meanwhile, revenue for its respiratory health category fell 3.4% over the same period on an organic basis.

Revenue in North America rose 1% on an organic basis to 932 million pounds, returning to growth despite a weak cold and flu season.

The company said it expects organic revenue growth of 3% to 5% for the full year.

Write to Aimee Look at aimee.look@wsj.com

(END) Dow Jones Newswires

April 29, 2026 03:48 ET (07:48 GMT)